Literature DB >> 21745515

Role of NOD1/CARD4 and NOD2/CARD15 gene polymorphisms in cancer etiology.

Anton G Kutikhin1.   

Abstract

NOD1/CARD4 and NOD2/CARD15 are members of Nod-like receptor family. They are located in cytosol, bind bacterial and viral ligands and play a key role in realization of innate and adaptive immune response, apoptosis, autophagy, and reactive oxygen species generation. Polymorphisms in NOD1/CARD4 and NOD2/CARD15 genes may shift balance between pro- and anti-inflammatory cytokines, modulating the risk of infection, chronic inflammation and cancer. NOD1/CARD4 and NOD2/CARD15 gene polymorphisms may be associated with altered risk of gastric, colorectal, breast, ovarian, prostate, testicular, lung, laryngeal, liver, gallbladder, biliary tract, pancreatic, small bowel, kidney, urinary bladder cancer, skin cancer, nonthyroid endocrine tumors, lymphoma and leukemia. The short list of such polymorphisms perspective for oncogenomic investigations may include rs2006847, rs2066845, rs2066844, rs2066842, ND(1)+32656, rs2075820 whereas rs104895493, rs104895476, rs104895475, rs104895474, rs104895473, rs104895472, rs104895462, rs104895461, rs104895460, rs104895438, rs5743291, rs5743260, rs2076756, rs2066843, Pro371Thr, Ala794Pro, Gln908His, rs72551113, rs72551107, rs6958571, rs2907749, rs2907748, rs2075822, rs2075819, rs2075818 may be added to the extended list. Reasons of discrepancies between different studies include confounding host genetic, bacterial, or environmental factors modulating penetrance of variant allele and affecting risk of condition increasing cancer risk, different bacterial impact in aetiology of such conditions, differences in sample size, clinicopathological characteristics, diagnostics, stratification, genotyping methods, and chance.
Copyright © 2011 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21745515     DOI: 10.1016/j.humimm.2011.06.003

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  38 in total

1.  NOD1 inhibits proliferation and enhances response to chemotherapy via suppressing SRC-MAPK pathway in hepatocellular carcinoma.

Authors:  Xiaomin Ma; Yumin Qiu; Lihui Zhu; Yunxue Zhao; Yueke Lin; Dapeng Ma; Zhenzhi Qin; Caiyu Sun; Xuecheng Shen; Tao Li; Lihui Han
Journal:  J Mol Med (Berl)       Date:  2019-12-23       Impact factor: 4.599

Review 2.  NOD2 mutations and colorectal cancer - Where do we stand?

Authors:  Diogo Branquinho; Paulo Freire; Carlos Sofia
Journal:  World J Gastrointest Surg       Date:  2016-04-27

3.  3020insC NOD2/CARD15 polymorphism associated with treatment of colorectal cancer.

Authors:  Inés Omrane; Amel Mezlini; Olfa Baroudi; Nejla Stambouli; Karim Bougatef; Hager Ayari; Imen Medimegh; Hassen Bouzaienne; Nancy Uhrhammer; Yves-Jean Bignon; Amel Benammar-Elgaaied; Raja Marrakchi
Journal:  Med Oncol       Date:  2014-04-10       Impact factor: 3.064

4.  New use for CETSA: monitoring innate immune receptor stability via post-translational modification by OGT.

Authors:  Walter R Drake; Ching-Wen Hou; Natasha E Zachara; Catherine Leimkuhler Grimes
Journal:  J Bioenerg Biomembr       Date:  2018-04-18       Impact factor: 2.945

5.  Inflammatory pathway genes associated with inter-individual variability in the trajectories of morning and evening fatigue in patients receiving chemotherapy.

Authors:  Fay Wright; Marilyn Hammer; Steven M Paul; Bradley E Aouizerat; Kord M Kober; Yvette P Conley; Bruce A Cooper; Laura B Dunn; Jon D Levine; Gail DEramo Melkus; Christine Miaskowski
Journal:  Cytokine       Date:  2017-01-19       Impact factor: 3.861

6.  NOD1, RIP2 and Caspase12 are potentially novel biomarkers for oral squamous cell carcinoma development and progression.

Authors:  Xiang Wang; Wenhui Jiang; Ning Duan; Yajie Qian; Qian Zhou; Pei Ye; Hongliu Jiang; Yang Bai; Weiyun Zhang; Wenmei Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

7.  Inflammatory-Related Genetic Variants in Non-Muscle-Invasive Bladder Cancer Prognosis: A Multimarker Bayesian Assessment.

Authors:  Alexandra Masson-Lecomte; Evangelina López de Maturana; Michael E Goddard; Antoni Picornell; Marta Rava; Anna González-Neira; Mirari Márquez; Alfredo Carrato; Adonina Tardon; Josep Lloreta; Montserrat Garcia-Closas; Debra Silverman; Nathaniel Rothman; Manolis Kogevinas; Yves Allory; Stephen J Chanock; Francisco X Real; Núria Malats
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-05-06       Impact factor: 4.254

8.  The role of NOD1/CARD4 and NOD2/CARD15 genetic variations in lung cancer risk.

Authors:  Cansu Ozbayer; Hulyam Kurt; Aysegul Bayramoglu; Hasan Veysi Gunes; Muzaffer Metintas; İrfan Degirmenci; Kevser Setenay Oner
Journal:  Inflamm Res       Date:  2015-08-04       Impact factor: 4.575

Review 9.  Therapeutic targeting of NOD1 receptors.

Authors:  L Moreno; T Gatheral
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

10.  Seven-gene signature on tumor microenvironment for predicting the prognosis of patients with pancreatic cancer.

Authors:  Bin Yang; Jinghua Xie; Zhiguo Li; Dan Su; Longfa Lin; Xiaofeng Guo; Zhiqiang Fu; Quanbo Zhou; Yanan Lu
Journal:  Gland Surg       Date:  2021-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.